Format

Send to

Choose Destination
Biol Aujourdhui. 2018;212(3-4):61-67. doi: 10.1051/jbio/2019011. Epub 2019 Apr 11.

[New frontiers in the fight against cancer].

[Article in French]

Author information

1
Innate Pharma Research Labs, Innate Pharma, 117 avenue de Luminy, 13009 Marseille, France.
2
Innate Pharma Research Labs, Innate Pharma, 117 avenue de Luminy, 13009 Marseille, France - Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France - Service d'Immunologie, Marseille Immunopôle, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 278 rue Saint-Pierre, 13005 Marseille, France.

Abstract

After many years of research, recent advances shed a new light on the role of the immune system in cancer. New therapeutic antibodies, such as anti-PD-1/L1, that block the interactions of inhibitory receptors (immune checkpoint inhibitors, ICI) with their ligands, have revolutionized the management of cancer patients. Nevertheless, they only affect a small part of the patient population. The main current challenge for immuno-oncology is to overcome these resistances by targeting new control points and new immune cells, combining these new immunotherapies with one another and with other standard treatments. Monalizumab is a novel antibody that simultaneously stimulates the anti-tumor action of NK and T cells by blocking one of their inhibitory receptors: NKG2A. NKG2A is present on the surface of both cell types and its ligand, HLA-E, and is very frequently overexpressed by human tumors, opening a wide therapeutic window to monalizumab.

PMID:
30973133
DOI:
10.1051/jbio/2019011

Supplemental Content

Loading ...
Support Center